Abstract | Insights From Murine Studies Regarding the Role of ApoA-I in Asthma | What Are the Potential Cellular Mechanisms by Which the ApoA-I/ABCA1 Pathway May Modulate Asthma Pathogenesis? | Insights From Human Studies Regarding the Role of apoA-I in Asthma | Can ApoA-I Be Developed Into a Novel Therapeutic Approach for Asthma? | Acknowledgments | References

New treatments are needed for patients with asthma who are refractory to standard therapies, such as individuals with a phenotype of “type 2-low” inflammation. This important clinical problem could potentially be addressed by the development of apolipoprotein A-I (apoA-I) mimetic peptides. ApoA-I interacts with its cellular receptor, the ATP-binding cassette subfamily A, member 1 (ABCA1), to facilitate cholesterol efflux out of cells to form nascent high-density lipoprotein particles. The ability of the apoA-I/ABCA1 pathway to promote cholesterol efflux from cells that mediate adaptive immunity, such as antigen-presenting cells, can attenuate their function…

Full text